MUSCULAR DYSTROPHY
INTRODUCTION
1 | P a g e
MUSCULAR DYSTROPHY
INTRODUCTION
Muscular dystrophy (abbreviated MD) refers to a group of muscle diseases that
weaken the muscles that move the human body. Muscular dystrophies are
characterized by progressive skeletal muscle weakness, defects in muscle proteins,
and the death of muscle cells and tissue. Nine diseases including Duchenne,
Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal,
distal, and Emery-Dreifuss are always classified as muscular dystrophy but there
are more than 100 diseases in total with similarities to muscular dystrophy. Most
types of MD are multi-system disorders with manifestations in body systems
including the heart, gastrointestinal and nervous systems, endocrine glands, skin,
eyes and other organs, namely the brain. The condition may also lead to mood
swings and learning difficulties.
In the 1860s, descriptions of boys who grew progressively weaker, lost the ability
to walk, and died at an early age became more prominent in medical journals. In
the following decade, French neurologist Guillaume Duchenne gave a
comprehensive account of 13 boys with the most common and severe form of the
disease (which now carries his name — Duchenne muscular dystrophy). It soon
became evident that the disease had more than one form, and that these diseases
affected males of all ages.
Muscular dystrophy (MD) is a genetic (inherited) condition that over time
gradually causes the muscles to weaken. This leads to an increasing level of
disability.
2 | P a g e
MUSCULAR DYSTROPHY
There are several different types of MD, with different symptoms and patterns of
progression. Not all types of MD cause severe disability, but there is currently no
cure for the condition.
MD is caused by mutations (cellular changes) in the genes that are responsible for
the structure and functioning of a person’s muscles. The mutations can occur
spontaneously, but they are normally inherited from a person’s parents.
The mutations cause changes in the muscle fibres, which interferes with the
muscle’s ability to function. Over time, this causes increasing disability.
Muscular dystrophies are a group of inherited muscle disorders in which one or
more genes needed for normal muscle function are defective, leading to muscle
weakness (see Symptoms and Diagnosis of Musculoskeletal Disorders: Weakness)
of varying severity. Other inherited muscle disorders include congenital
myopathies, periodic paralysis, and glycogen storage diseases.
Glycogen storage diseases are a group of rare inherited disorders in which muscles
cannot metabolize sugars normally (see Hereditary Metabolic Disorders: Glycogen
Storage Diseases), so they build up large stores of glycogen (a starch that is formed
from sugars).
Muscular dystrophy is the term used to describe a group of diseases of the muscles.
With muscular dystrophy the muscles become weak and can waste
away.There are over 20 different kinds of muscular dystrophies.
The number of people affected by muscular dystrophy depends on the
specific type. For example,approximately one child in 4,000 will have
Spinal Muscular Atrophy. 3 | P a g e
MUSCULAR DYSTROPHY
Approximately one in 3,000 will have Duchenne Muscular Dystrophy. The
different types of muscular dystrophy have different causes.
Some have genetic causes. A virus or illness causes some. Others have
unknown causes.
To diagnose muscular dystrophy a doctor will take a detailed history,
perform a thorough physical examination, and conduct specific tests.
One of these tests is an electromyogram (EMG), which measuresthe
electrical activity of the muscles.
If a diagnosis cannot be made based on these tests, a muscle biopsy is
oftenThese tests usually give the diagnosis in about 80% of the patients.
However, even with new tests approximately 15%-20% of patients will go
undiagnosed.
Some of the health problems that people with muscle diseases can
experience are problems with breathing and/or heart problems.
Many patients can develop curvature of the spine (scoliosis) or muscle
contractions leading to the need for surgery.
The treatment depends upon the specific cause of muscle weakness.
However, physical therapy and occupational therapy are often used. In some
cases a person with a muscle disease will get worse over time, and may have
a shorter life expectancy than someone without the disease. However, some
of the muscle diseases do not affect life expectancy at all.
4 | P a g e
MUSCULAR DYSTROPHY
DEFINITION
5 | P a g e
MUSCULAR DYSTROPHY
DEFINITION:-
One of a group of genetic diseases characterized by progressive weakness and
degeneration of the skeletal or voluntary muscles which control movement. The
muscles of the heart and some other involuntary muscles are also affected in some
forms of muscular dystrophy, and a few forms involve other organs as well.
Guillaume-Benjamin-Amand Duchenne, 1987
Inherited disease that causes progressive weakness in the skeletal (and occasionally
heart) muscle. Muscle tissue degenerates and regenerates randomly and is replaced
by scar tissue and fat.
Britannica Concise Encyclopaedia, 1999
Muscular dystrophies (MD) are inherited disorders characterized by progressive
weakness and degeneration of the skeletal or voluntary muscles which control
movement, without a central or peripheral nerve abnormality. The muscles of the
heart and other involuntary muscles are also affected in some forms of MD, and a
few forms involve other organs as well.
Neurological Disorder Journals, 2000
6 | P a g e
MUSCULAR DYSTROPHY
REVIEW
OF
LITERATURE
A B S T R A C T7 | P a g e
MUSCULAR DYSTROPHY
Lunt and Harper et al (1991) concluded that there is a dominantly inherited
scapulohumeral or scapuloperoneal syndrome genetically distinct from FSHD that
does not have facial weakness as a feature. Many cases (as much as 25%) may
represent new, ex-novo mutations.
Alan E H Emery et al 1954 stated that muscular dystrophies are a group of
genetic diseases that severely affect children and adults. For sufferers and their
family, the illness presents enormous physical and psychological challenges.
C. Jimenez-Mallebrera, S. C. Brown, C. A. Sewry and F. Muntoni et al
December 2004 congenital muscular dystrophies are a clinically and genetically
heterogeneous group of neuromuscular disorders. Each form has a characteristic
phenotype, but there is overlap between some entities and their classification is
based on a combination of clinical features and the primary or secondary protein
defect.
Josef Finsterer et al 17 July 2006 becomes “definite” in all patients with MD,
BMD, and MMP, but progresses markedly only in BMD patients within 10 years.
MD, BMD, or MMP patients should be cardiologically investigated as soon as the
neurological diagnosis is established and treated if CI becomes symptomatic, or in
case of severe ECG or echocardiographic abnormalities.
8 | P a g e
MUSCULAR DYSTROPHY
Stamulumab et al 2005/2006 trial was completed by Wyeth in Collegeville, PA.
As of April 2007, the results of the study have not yet been made public, but it is
one of the few known drugs in development for the treatment for muscular
dystrophy. Myostatin is a protein that inhibits the growth of muscle tissue, MYO-
029 is a recombinant human antibody designed to bind and inhibit the activity of
myostatin.
Abu-Baker A, Rouleau GA et al 2003 made experiments and finally made a
conculsion that Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset
disorder characterized by progressive eyelid drooping, swallowing difficulties and
proximal limb weakness. OPMD is caused by a small expansion of a short
polyalanine tract in the poly (A) binding protein nuclear 1 protein (PABPN1).
QH Leyten et al – 1996 Congenital muscular dystrophy (CMD) is a condition
in which there are already at birth, marked hypotonia, generalized muscle
weakness and frequently multiple contractures. CMD has recently been classified
into four categories: CMD I, the classical or ‘pure’ CMD without severe
impairment of intellectual development; CMD II, the Fukuyama type CMD with
muscle and structural brain abnormalities.
B. G. M. van Engelen et al 16 December 1999 Central nervous system (CNS)
characteristics were examined in seventeen patients with autosomal recessive
classic or “pure” congenital muscular dystrophy (CMD). In three patients,
neuroradiological examination (CT/MRI) indicated hypodense white matter areas.
Two out of these three patients had epilepsy (seizures and epileptic discharges on
their EEG)
9 | P a g e
MUSCULAR DYSTROPHY
F. J. M. Gabreëls et al 19 March 1999 conducted an experiment on congenital
muscular dystrophy (CMD) in a 13-year-old girl with early manifestation of
muscle weakness and hypotonia, severe contractures, bulbar syndrome,
progressive external ophtalmoplegia, and white matter changes on magnetic
resonance imaging (MRI) of the brain, but no mental defect. Serum creatine
kinase (CK) level was normal.
Jennifer E. Morgan et al 26 August 2002 observed that Steroids represent the
only pharmacological palliative treatment for Duchenne muscular dystrophy.
However, they do have side effects and despite a large number of published studies
showing their efficacy, they are still not universally used. This is largely due to the
lack of functional outcome and quality of life measures in most of the published
studies and suggests that further trials might be required to answer some of the still
unclear aspects of their role.
Sara T Winokur et al 19 November 2002 reported that the myoblasts suggests
that aberrant gene expression occurs early in facioscapulohumeral muscular
dystrophy muscle development. In order to test this hypothesis, global gene
expression profiling and in vitro characterization of facioscapulohumeral muscular
dystrophy and control myoblasts were carried out.
Silvère M. van der Maarel et al 30 May 2006 Clinical trials based on suppression
of inflammatory reactions or increasing muscle mass by drugs or training have
been disappointing. A recent, probably the first evidence-based pilot trial to revert
epigenetic changes did also not provide grounds for a larger clinical study. Clearly,
better disease models need to be developed to identify and test novel intervention
strategies to eventually improve the quality of life for patients with FSHD.
10 | P a g e
MUSCULAR DYSTROPHY
Rabi Tawil et al 3 October 2008 reveals that Autosomal dominant
facioscapulohumeral muscular dystrophy (FSHD) is mainly characterized by
progressive wasting and weakness of the facial, shoulder, and upper-arm muscles.
FSHD is caused by contraction of the macrosatellite repeat D4Z4 on chromosome
4q35. The D4Z4 repeat is very polymorphic in length, and D4Z4 rearrangements
occur almost exclusively via intrachromosomal gene conversions.
H. Lidov et al manufestated a prototypical form is Duchenne muscular dystrophy,
an X-linked disorder, but there are nearly 20 rarer similar disorders called limb-
girdle dystrophies or congenital muscular dystrophies. Duchenne dystrophy is
caused by loss of dystrophin, a 427 kDa cytoskeletal actin-binding protein. A
cluster of proteins that form an integral membrane complex (dystroglycans,
sarcoglycans) links dystrophin to the extracellular matrix.
Kate Bushby et al 27 September 2006 stated that The limb-girdle muscular
dystrophies are a group of disorders where our understanding of their underlying
molecular basis has made huge strides over the past years, revealing great
heterogeneity at the clinical and molecular level.
11 | P a g e
MUSCULAR DYSTROPHY
TYPES
12 | P a g e
MUSCULAR DYSTROPHY
Types
1. Duchenne muscular dystrophy
2. Becker's muscular dystrophy
3. Congenital muscular dystrophy
4. Distal muscular dystrophy
5. Emery-Dreifuss muscular dystrophy
6. Facioscapulohumeral muscular dystrophy
7. Limb-girdle muscular dystrophy
8. Myotonic muscular dystrophy
9. Oculopharyngeal muscular dystrophy
10. Spinal muscular atrophy
13 | P a g e
MUSCULAR DYSTROPHY
Duchenne muscular dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is a severe recessive X-linked form of
muscular dystrophy characterized by rapid progression of muscle degeneration,
eventually leading to loss of ambulation and death. This affliction affects one in
3500 males, making it the most prevalent of muscular dystrophies. In general, only
males are afflicted, though females can be carriers. Females may be afflicted if the
father is afflicted and the mother is also a carrier/ affected. The disorder is caused
by a mutation in the gene DMD, located in humans on the X chromosome (Xp21).
The DMD gene codes for the protein dystrophin, an important structural
component within muscle tissue. Dystrophin provides structural stability to the
dystroglycan complex (DGC), located on the cell membrane.
Symptoms usually appear in male children before age 5 and may be visible in early
infancy. Progressive proximal muscle weakness of the legs and pelvis associated
with a loss of muscle mass is observed first. Eventually this weakness spreads to
the arms, neck, and other areas. Early signs may include pseudohypertrophy
(enlargement of calf and deltoid muscles), low endurance, and difficulties in
standing unaided or inability to ascend staircases. As the condition progresses,
muscle tissue experiences wasting and is eventually replaced by fat and fibrotic
tissue (fibrosis). By age 10, braces may be required to aid in walking but most
patients are wheelchair dependent by age 12. Later symptoms may include
abnormal bone development that lead to skeletal deformities, including curvature
14 | P a g e
MUSCULAR DYSTROPHY
of the spine. Due to progressive deterioration of muscle, loss of movement occurs
eventually leading to paralysis. Intellectual impairment may or may not be present
but if present, does not progressively worsen as the child ages.
Becker's muscular dystrophy
A form of muscular dystrophy that is quite similar to Duchenne muscular
dystrophy, except that patients with Becker do produce some of the key protein,
dystrophin, whereas those with Duchenne do not. Progression of the disease in
Becker type is slower than in Duchenne, and symptoms may appear as late as the
mid-twenties.
Becker muscular dystrophy (also known as Benign
pseudohypertrophic muscular dystrophy) is an X-linked recessive inherited
disorder characterized by slowly progressive muscle weakness of the legs and
pelvis.
It is a type of dystrophinopathy, which includes a spectrum of muscle diseases in
which there is insufficient dystrophin produced in the muscle cells, resulting in
instability in the structure of muscle cell membrane. This is caused by mutations in
the dystrophin gene, which encodes the protein dystrophin. Becker muscular
dystrophy is related to Duchenne muscular dystrophy in that both result from a
mutation in the dystrophin gene, but in Duchenne muscular dystrophy no
functional dystrophin is produced making DMD much more severe than BMD.
Both Duchenne and Becker muscular dystrophy have traditionally been called "X-
linked" recessive diseases, but in view of modern molecular biology and
identification of the dystrophin gene, it might be more appropriate to say they are
X-chromosome recessive diseases.15 | P a g e
MUSCULAR DYSTROPHY
Figure No-1.1 shows the involvement of body parts for Duchenne and Becker’s
type.
16 | P a g e
MUSCULAR DYSTROPHY
Congenital muscular dystrophy
Congenital muscular dystrophy (CMD) is the term used to describe muscular
dystrophy that is present at birth. CMD describes a number of autosomal recessive
diseases of muscle weakness and possible joint deformities, present at birth and
slowly progressing. Life expectancies for affected individuals vary, although some
forms of CMD do not affect life span at all.
All such known dystrophies are genetically recessive and result from mutations in
a variety of different genes, including those encoding the laminin-α2 chain,
fukutin-related protein, LARGE and fukutin, amongst others. Currently there is no
cure. Physical and occupational therapy, surgery, wheelchairs and other assistive
technology may be helpful.
Congenital myopathies (including X-linked myotubular myopathy and nemaline
myopathy) typically have normal or near-normal serum CK concentration and
evidence of developmental rather than dystrophic muscle abnormalities on muscle
biopsy. Congenital muscular dystrophy type 1C (MDC1C). MDC1C is a severe
form of CMD with partial merosin deficiency and a partial deficiency of alpha
dystroglycan.
This form of CMD has been mapped to chromosome 19q13.3 with
homozygous mutations identified in the FKRP gene. Mutations in this 12-kb gene,
which is composed of three non-coding exons and one large coding exon, is also
17 | P a g e
MUSCULAR DYSTROPHY
the cause of LGMD2I (see Limb-Girdle Muscular Dystrophy Overview), which,
despite a variable phenotype, is milder in presentation than MDC1C.
While one common mutation has been identified in FKRP, this mutation has
only been observed in persons with LGMD2I and has not been seen in MDC1C.
Brown et al (2004) correlated both the mutation type and expression of alpha
dystroglycan with the disease phenotype. Specifically, persons with MDC1C
consistently show a severe deficiency of alpha dystroglycan and are either
compound heterozygotes for one missense mutation and one nonsense mutation or
have two missense mutations. Conversely, individuals with LGMD2I have the
common mutation (C826A) and either a missense or nonsense mutation, and only
mild to moderately decreased alpha dystroglycan. Individuals with mild LFMD2I
are homozygous for the common mutation and show only a mild deficiency of
alpha dystroglycan.
18 | P a g e
MUSCULAR DYSTROPHY
Distal muscular dystrophy
One of two genetic muscle diseases characterized by wasting of the muscles most
distant from the midline, such as those of the hands and feet. Both types of distal
MD are inherited in an autosomal dominant manner and may affect males and
females.
The first type of distal MD starts in infancy, does not progress after adolescence,
and is not debilitating. The second type of distal MD starts after age 40, affects the
muscles of the hands and feet and then the muscles closer to the trunk but does not
shorten the life span.
Emery-Dreifuss muscular dystrophy
Abbreviated EDMD. A form of muscular dystrophy that begins in childhood or
adolescence as a slowly progressive disorder of the upper arms or upper legs
characterized by weakness and atrophy of muscles without involvement of the
nervous system. Contractures of the limbs, especially the elbows, are common
complications, as are serious heart problems.
EDMD is caused by mutation in the gene encoding emerin in chromosome band
Xq28. Although only males have the muscle problems associated with EDMD,
females may have the heart problems. Accordingly, female relatives of males with
this disorder should have regular heart check-ups.
There are two other known types of EDMD. Both are caused by mutation in the
lamin A gene (LMNA). One displays similar features to EDMD and is inherited in
19 | P a g e
MUSCULAR DYSTROPHY
an autosomal dominant manner; it is classified as EDMD type 2. The other type
appears to lack cardiac problems and is inherited in an autosomal recessive
manner; it is EDMD type 3.
Mutations in the EMD and LMNA genes cause Emery-Dreifuss muscular
dystrophy. The EMD and LMNA genes provide instructions for making proteins
that are components of the nuclear envelope, which surrounds the nucleus in cells.
The nuclear envelope regulates the movement of molecules into and out of the
nucleus, and researchers believe it may play a role in regulating the activity of
certain genes.
Most cases of Emery-Dreifuss muscular dystrophy are caused by mutations
in the EMD gene. This gene provides instructions for making a protein
called emerin, which appears to be essential for the normal function of
skeletal and cardiac muscle. Most EMD mutations prevent the production of
any functional emerin. It remains unclear how a lack of this protein results in
the signs and symptoms of Emery-Dreifuss muscular dystrophy.
Less commonly, Emery-Dreifuss muscular dystrophy results from mutations
in the LMNA gene. This gene provides instructions for making two very
similar proteins, lamin A and lamin C. Most of the LMNA mutations that
cause this condition result in the production of an altered version of these
proteins.
20 | P a g e
MUSCULAR DYSTROPHY
Figure No-1.2 shows the involvement of body parts for Emery-Dreifuss muscular
dystrophy.
21 | P a g e
MUSCULAR DYSTROPHY
Facioscapulohumeral muscular dystrophy
A form of muscular dystrophy that begins before age 20 with slowly
progressive weakness of the muscles of the face, shoulders, and feet. The severity
of the disease is variable. Although most people with facioscapulohumeral
muscular dystrophy (FSHD) retain the ability to walk, about 20% of affected
individuals require a wheelchair. Life expectancy is not shortened.
The diagnosis of FSHD can be confirmed by a DNA test disclosing the deletion of
copies of a repeat motif called D4Z4 on chromosome 4. FSHD is inherited in an
autosomal dominant manner. Offspring of an affected individual have a 50%
chance of inheriting the mutant at 4. About 10-30% of cases are due to a new
mutation. Prenatal testing is available.
More than 95% of cases of FSHD are associated with the deletion of integral
copies of a tandemly repeated 3.2kb unit (D4Z4 repeat) at the subtelomeric
region 4q35 of the Human genome of which a normal chromosome will
include between 11-150 repetitions of D4Z4.
There are both heterochromatin and euchromatin structures within D4Z4 and
one putative gene called DUX4.
Inheritance is autosomal dominant, though up to one-third of the cases
appear to be the result of de novo (new) mutations.
The heterochromatin is specifically lost in the deletions of FSHD while the
euchromatin structures remain.
22 | P a g e
MUSCULAR DYSTROPHY
If the entire region is removed, there are birth defects, but no specific defects
on skeletal muscle.
Individuals appear to require the existence of 11 or fewer repeat units to be
at risk for FSHD. Though the nature of the DNA mutation is known, it has
not been possible to identify a gene or mechanism that causes FSHD and a
novel position effect has been postulated to explain the disease phenotype.
In addition, a few cases of FSHD are the result of rearrangements between
subtelomeric chromosome 4q and a subtelomeric region of 10q. This
location contains a tandem repeat structure highly homologous to 4q35.
Disease occurs when the translocation results in a critical loss of tandem
repeats to the 4q site.
23 | P a g e
MUSCULAR DYSTROPHY
Figure no-1.3 shows the involvement of body parts for Facioscapulohumeral
muscular dystrophy.
24 | P a g e
MUSCULAR DYSTROPHY
Limb-girdle muscular dystrophy
Limb-girdle muscular dystrophy or Erb's muscular dystrophy is an
autosomal class of muscular dystrophy that is similar but distinct from
Duchenne muscular dystrophy and Becker's muscular dystrophy. Limb-
girdle muscular dystrophy encompasses a large number of rare disorders.
The term "limb-girdle" is used to describe these disorders because the
muscles most severely affected are generally those of the hips and shoulders
-- the limb girdle muscles.
Common symptoms of limb-girdle muscular dystrophy are muscle
weakness, myoglobinuria, pain, myotonia, cardiomyopathy, elevated serum
CK, and rippling muscles.
The muscle weakness is generally symmetric, proximal, and slowly
progressive.
In most cases, pain is not present with LGMD, and mental function is not
affected.
LGMD can begin in childhood, adolescence, young adulthood or even later.
The age of onset is usually between 10 and 30. Both genders are affected
equally. When limb-girdle muscular dystrophy begins in childhood the
progression appears to be faster and the disease more disabling. When the
disorder begins in adolescence or adulthood the disease is generally not as
severe and progresses more slowly.
25 | P a g e
MUSCULAR DYSTROPHY
There is no sensory neuropathy or autonomic or visceral disfunction at
presentation.the specific dermatomes affected can be demonstrated
clinically,and although lower limb deep tendon reflexes and plantar reflex
are lost, abdominal reflexes are preserved
One of a group of diseases that may begin in childhood or later with slowly
progressive weakness and wasting of the muscles restricted to the limb
musculature, especially to the hips and shoulders.
Muscle biopsies of the limb-girdle muscular dystrophies typically show
degeneration and regeneration of muscle (dystrophic biopsy). There is
usually an elevated CPK (creatine phosphokinase) in the blood.
Most patients show relative sparing of the heart and bulbar muscles. The
limb-girdle muscular dystrophies are caused a number of genetic defects and
can affect both males and females. Inheritance is usually autosomal
recessive or, more rarely, autosomal dominant.
26 | P a g e
MUSCULAR DYSTROPHY
Figure no-1.3 shows the involvement of body parts for Limb-girdle muscular
dystrophy
Myotonic muscular dystrophy
An inherited disease in which the muscles contract but have decreasing power to
relax -- this phenomenon is termed myotonia (irritability and prolonged contraction
of muscles). The disease also leads to a mask-like expressionless face, premature
balding, cataracts, and heart arrhythmias (abnormalities in heart rhythm). The onset
of such problems is usually in young adulthood. However, onset can be at any age
and the disease is extremely variable in the degree of severity.
Myotonic dystrophy is due to a trinucleotide repeat (a "stuttering" sequence of
three bases) in the DNA. The myotonic dystrophy gene (called DM1), found on
27 | P a g e
MUSCULAR DYSTROPHY
chromosome 19q13.3, codes for a protein kinase (an enzyme) that is found in
skeletal muscle.
An unusual feature is that the signs and symptoms of the disease usually become
more severe with each successive generation. This is because mistakes in the
faithful copying of the gene from one generation to the next result in the
amplification of a genomic "AGC/CTG triplet repeat." Unaffected individuals have
between 5 and 27 copies of AGC/CTG, myotonic dystrophy patients who are
minimally affected have at least 50 repeats, while more severely affected patients
have an expansion of up to several kilobase pairs.
Oculopharyngeal muscular dystrophy
A form of muscular dystrophy that begins in the muscles of the eyes and
throat. It usually appears between the ages of 40 and 60, and progresses slowly.
Oculopharyngeal muscular dystrophy is inherited in an autosomal dominant
manner and affects both males and females. It may be more than one disease. One
type is caused by mutation in the PABP2 gene on chromosome 14 encodes
poly(A)-binding protein-2.
28 | P a g e
MUSCULAR DYSTROPHY
Figure no-1.4 shows the involvement of body parts for Oculopharyngeal muscular
dystrophy
Spinal muscular atrophy
Spinal Muscular Atrophy (SMA) is a neuromuscular disease characterized by
degeneration of motor neurons, resulting in progressive muscular atrophy (wasting
away) and weakness. The clinical spectrum of SMA ranges from early infant death
to normal adult life with only mild weakness. These patients often require
comprehensive medical care involving multiple disciplines, including pediatric
pulmonology, pediatric neurology, pediatric orthopedic surgery, Lower Extremity
29 | P a g e
MUSCULAR DYSTROPHY
& Spinal Orthosis, pediatric critical care, and physical medicine and rehabilitation;
and physical therapy, occupational therapy, respiratory therapy, and clinical
nutrition. Genetic counseling is also helpful for the parents and family members.
Sensation and the ability to feel are not affected. Intellectual activity is normal and
it is often observed that patients with SMA are unusually bright and sociable.
In all of its forms, the primary feature of SMA is muscle weakness, accompanied
by atrophy of muscle. This is the result of denervation, or loss of the signal to
contract, that is transmitted from the spinal cord. This is normally transmitted from
motor neurons in the spinal cord to muscle via the motor neuron's axon, but either
the motor neuron with its axon, or the axon itself, is lost in all forms of SMA.
The features of SMA are strongly related to its severity and age of onset. SMA
caused by mutation of the SMN gene has a wide range, from infancy to adult, fatal
to trivial, with different affected individuals manifesting every shade of
impairment between these two extremes. Many of the symptoms of SMA relate to
secondary complications of muscle weakness, and as such can be at least partially
remediated by prospective therapy.
Infantile SMA is the most severe form. Some of the symptoms include:
Muscle weakness
Poor muscle tone
Weak cough
Limpness or a tendency to flop
30 | P a g e
MUSCULAR DYSTROPHY
Difficulty sucking or swallowing
Accumulation of secretions in the lungs or throat
Bell-shaped torso, caused by breathing using muscles around the tummy
area
Clenched fists with sweaty hands
Flickering/vibrating of the tongue
Head often tilted to one side, even when lying down
Legs that tend to be weaker than the arms
Legs lying in the "frogs leg" position
Hypotonia, areflexia, and multiple congenital contractures (arthrogryposis)
associated with loss of anterior horn cells
Feeding difficulties
Increased susceptibility to respiratory tract infections
Bowel/bladder weakness
Lower-than-normal weight
Developmental milestones , such as lifting the head or sitting up, can't be
reached
31 | P a g e
MUSCULAR DYSTROPHY
AETIOLOGY
32 | P a g e
MUSCULAR DYSTROPHY
AETIOLOGY
All muscular dystrophies are inherited (genetic) conditions (even though some
forms may form from an ex-novo mutation). Different muscular dystrophies follow
various inheritance patterns:
Duchenne muscular dystrophy (DMD)
It is inherited in an X-linked recessive pattern, meaning that the mutated
gene that causes the disorder is located on the X chromosome (one of the
two sex chromosomes, the other being Y) and is thus considered sex-linked.
In males (who have only one X chromosome) one altered copy of the gene
in each cell is sufficient to cause the condition. In females (who have two X
chromosomes) a mutation must generally be present in both copies of the
gene to cause the disorder (relatively rare exceptions, manifesting carriers,
do occur due to dosage compensation/X-inactivation). Males are therefore
affected by X-linked recessive disorders much more often than females.
A characteristic of X-linked inheritance is that fathers cannot pass X-
linked traits to their sons. In about two thirds of DMD cases, an affected
male inherits the mutation from a mother who carries one altered copy of the
DMD gene. The other one third of cases probably result from new mutations
in the gene. Females who carry one copy of a DMD mutation may have
some signs and symptoms related to the condition (such as muscle weakness
and cramping), but these are typically milder than the signs and symptoms
seen in affected males.
33 | P a g e
MUSCULAR DYSTROPHY
Duchenne muscular dystrophy and Becker's muscular dystrophy are caused
by mutations of the gene for the dystrophin protein and lead to an
overabundance of the enzyme creatine kinase.
Myotonic Muscular Dystrophy
Autosomal dominant pattern of inheritance. Myotonic dystrophy results
from the expansion of a short repeat in the DNA sequence (CTG in one gene
or CCTG in another gene). In other words, the the gene defect is an
abnormally long repetition of a three- or four-letter "word" in the genetic
code. While the exact mechanism of action is not known, this molecular
change may interfere with the production of important muscle proteins
Limb-Girdle Muscular Dystrophy
Many forms of LGMD have been identified, showing different patterns of
inheritance (autosomal recessive vs. autosomal dominant). In an autosomal
recessive pattern of inheritance, an individual receives two copies of the
defective gene, one from each parent. The recessive LGMDs are more
frequent than the dominant forms. The dominant LGMDs usually show adult
onset. Some of the recessive forms have been associated with defects in
proteins that make up the dystrophin-glycoprotein complex.
The term "limb-girdle" is used to describe these disorders because the
muscles most severely affected are generally those of the hips and shoulders
-- the limb girdle muscles.
34 | P a g e
MUSCULAR DYSTROPHY
The muscle weakness is generally symmetric, proximal, and slowly
progressive.
In most cases, pain is not present with LGMD, and mental function is
not affected.
LGMD can begin in childhood, adolescence, young adulthood or even
later. The age of onset is usually between 10 and 30. Both genders are
affected equally. When limb-girdle muscular dystrophy begins in
childhood the progression appears to be faster and the disease more
disabling. When the disorder begins in adolescence or adulthood the
disease is generally not as severe and progresses more slowly.
There is no sensory neuropathy or autonomic or visceral disfunction at
presentation.the specific dermatomes affected can be demonstrated
clinically,and although lower limb deep tendon reflexes and plantar
reflex are lost, abdominal reflexes are preserved
Congenital Muscular Dystrophy
Autosomal recessive or autosomal dominant; these diseases are sometimes
inherited through both parents and sometimes inherited from one parent.
They can also occur spontaneously because of a newly developed genetic
mutation
Congenital muscular dystrophy (CMD) is the term used to describe
muscular dystrophy that is present at birth. CMD describes a number
of autosomal recessive diseases of muscle weakness and possible joint
deformities, present at birth and slowly progressing. Life expectancies
for affected individuals vary, although some forms of CMD do not
affect life span at all.
35 | P a g e
MUSCULAR DYSTROPHY
All such known dystrophies are genetically recessive and result from
mutations in a variety of different genes, including those encoding the
laminin-α2 chain, fukutin-related protein, LARGE and fukutin,
amongst others. Currently there is no cure. Physical and occupational
therapy, surgery, wheelchairs and other assistive technology may be
helpful.
Distal Muscular Dystrophy
May be autosomal dominant, (a faulty gene is inherited from one
parent); or autosomal recessive (when a faulty gene is inherited from
both parents).
Distal muscular dystrophy (or distal myopathy) is a group of disorders
characterized by onset in the hands or feet.
Many types involve dysferlin, but it has been suggested that not all
cases do
Facioscapulohumeral Muscular Dystrophy
More than 95% of cases of FSHD are associated with the deletion of integral
copies of a tandemly repeated 3.2kb unit (D4Z4 repeat) at the subtelomeric
region 4q35 of the Human genome of which a normal chromosome will
include between 11-150 repetitions of D4Z4. There are both heterochromatin
and euchromatin structures within D4Z4 and one putative gene called DUX4.
Inheritance is autosomal dominant, though up to one-third of the cases appear
to be the result of de novo (new) mutations. The heterochromatin is
specifically lost in the deletions of FSHD while the euchromatin structures
36 | P a g e
MUSCULAR DYSTROPHY
remain. If the entire region is removed, there are birth defects, but no specific
defects on skeletal muscle. Individuals appear to require the existence of 11 or
fewer repeat units to be at risk for FSHD. Though the nature of the DNA
mutation is known, it has not been possible to identify a gene or mechanism
that causes FSHD and a novel position effect has been postulated to explain the
disease phenotype.
Emery-Dreifuss Muscular Dystrophy
Can be X-linked recessive, primarily affecting males, who inherit the disease
through their mothers. Another type is autosomal dominant, meaning it can
be inherited through either parent; an autosomal recessive type occurs when
a faulty gene is inherited from both parents.
Among the earliest features of this disorder are joint deformities called
contractures, which restrict the movement of certain joints. Contractures
become noticeable in early childhood to teenage years and most often
involve the elbows, ankles, and neck. Most affected individuals also
experience slowly progressive muscle weakness and wasting, beginning in
muscles of the upper arms and lower legs and progressing to muscles in the
shoulders and hips. A power chair or scooter or wheelchair may be needed
by adulthood.
Almost all people with Emery-Dreifuss muscular dystrophy have heart
problems by adulthood. In many cases, these heart problems stem from
abnormalities of the electrical signals that control the heartbeat (cardiac
conduction defects) and abnormal heart rhythms (arrhythmias). If untreated,
37 | P a g e
MUSCULAR DYSTROPHY
these abnormalities can lead to an unusually slow heartbeat (bradycardia),
fainting (syncope), and an increased risk of stroke and sudden death.
Oculopharyngeal Muscular Dystrophy
May be autosomal dominant, meaning OPMD is inherited from one
parent; or autosomal recessive, occurring when a faulty gene is
inherited from each parent.
Abnormal vacuoles within muscle fibres. A distinction between OPD
and myasthenia gravis or mitochondrial myopathy must be made. The
absence of family history and the fluctuation of symptoms in
myasthenia gravis usually distinguish the two conditions
38 | P a g e
MUSCULAR DYSTROPHY
PATHO-
PHYSIOLOGY
Duchenne muscular dystrophy and Becker muscular dystrophy:-39 | P a g e
MUSCULAR DYSTROPHY
Devastating inherited neuromuscular disorder that affects one in 3300 live male
births. Although the responsible gene and its product, dystrophin, have been
characterized for more than 15 years, and a mouse model (mdx) has been
developed, comprehensive understanding of the mechanism leading from the
absence of dystrophin to the muscular degeneration is still debated. First,
dystrophin is considered a key structural element in the muscle fiber, and the
primary function of the dystrophin-associated protein complex is to stabilize
plasma membrane, although a role of signaling is still possible. Mechanically
induced damage through eccentric contractions puts a high stress on fragile
membranes and provokes micro-lesions that could eventually lead to loss of
calcium homeostasis, and cell death. Altered regeneration, inflammation, impaired
vascular adaptation, and fibrosis are probably downstream events that take part in
the muscular dystrophy and that probably vary a lot along species (i.e., mdx mice),
probands within families, stressing the importance of epigenic factors.
Because no etiologic therapy is available for Duchenne muscular dystrophy,
a better understanding of the primary and downstream mechanisms could prove
useful for producing new adjuvant treatments. All pathophysiologic mechanisms
are reviewed together with perspectives on management.
Facioscapulohumeral muscular dystrophy
40 | P a g e
MUSCULAR DYSTROPHY
The exact pathophysiology of FSHD remains unknown as of March 2007. Muscle
histologic changes are nonspecific for the muscle wasting. There is evidence of
early inflammatory changes in the muscle, but reported responses to high dose
open labeled corticosteroid treatment have been negative. Animal studies of
anabolic effects of beta adrenergic agonists on models of muscle wasting led to an
open trial of albuterol (a beta adrenergic agonist) in which limited preliminary
results support an improvement of muscle mass and strength in FSHD. Preliminary
studies of muscle cultures suggest an increased sensitivity to oxidative stress, but
require further exploration.
Myotonic dystrophy
Myotonic dystrophy (DM) is a clinically and genetically heterogeneous disorder.
There are two major forms:
DM1, for a century known as Steinert's disease
DM2, recognized in 1994 as a milder version of DM1.
These autosomal dominant conditions are among the most common forms of adult-
onset muscular dystrophy. However, DM is more than simply a muscular
dystrophy per se, since affected individuals may show cataracts, cardiac
conduction abnormalities, infertility, and insulin resistance. Furthermore, there is a
severe congenital form of DM1 with marked developmental disability.
Limb-girdle muscular dystrophy
41 | P a g e
MUSCULAR DYSTROPHY
It is typically an inherited disorder, though it may be inherited as a dominant,
recessive, or X-linked genetic defect. The result of the defect is that the muscles
cannot properly form the proteins needed for normal muscle function. Several
different proteins can be affected, and the specific protein that is absent or
defective identifies the specific type of muscular dystrophy.
Emery-Dreifuss muscular dystrophy
Mutations in the EMD and LMNA genes cause Emery-Dreifuss muscular
dystrophy. The EMD and LMNA genes provide instructions for making proteins
that are components of the nuclear envelope, which surrounds the nucleus in cells.
The nuclear envelope regulates the movement of molecules into and out of the
nucleus, and researchers believe it may play a role in regulating the activity of
certain genes.
Most cases of Emery-Dreifuss muscular dystrophy are caused by mutations in the
EMD gene. This gene provides instructions for making a protein called emerin,
which appears to be essential for the normal function of skeletal and cardiac
muscle. Most EMD mutations prevent the production of any functional emerin. It
remains unclear how a lack of this protein results in the signs and symptoms of
Emery-Dreifuss muscular dystrophy.
Less commonly, Emery-Dreifuss muscular dystrophy results from mutations in the
LMNA gene. This gene provides instructions for making two very similar proteins,
lamin A and lamin C. Most of the LMNA mutations that cause this condition result
in the production of an altered version of these proteins.
42 | P a g e
MUSCULAR DYSTROPHY
SIGNS
AND
SYMPTOMS
43 | P a g e
MUSCULAR DYSTROPHY
Signs and symptoms
Main symptoms include:
Progressive muscular wasting
Poor balance
Frequent falls
Walking difficulty
Waddling gait
Calf deformation
Limited range of movement
Respiratory difficulty
Drooping eyelids
Gonadal
Loss of bladder control
Scoliosis (curvature of the spine and the back)
Inability to walk
Few or none of these symptoms may be present before diagnosis. Some types of
muscular dystrophy can affect the heart, causing cardiomyopathy or arrhythmias
44 | P a g e
MUSCULAR DYSTROPHY
NOTE: There are different types of muscular dystrophy, each affecting different sets of muscles and resulting in
different degrees of muscle weakness.
Type of Muscular Dystrophy Description Symptoms
Duchenne muscular dystrophy • most common and the
most severe
• 1 out of every 3,500 boys
(Girls can carry the gene
that causes the disease, but
they usually have no
symptoms)
• begins to appear around age 5, as the pelvic
muscles begin to weaken
• muscles weaken in the shoulders, back, arms,
and legs
• eventually, the respiratory muscles are
affected, and a ventilator is required to assist
breathing
• kids: a life span of about 20 years, about one-
third of them experience learning disabilities
and a small number having mental retardation
Becker muscular dystrophy • less common and
progresses more slowly
• affects approximately 1 in
30,000 boys
• caused by insufficient
production of dystrophin
• begins during the teen years
• muscle weakness first begins in the pelvic
muscles, then moves into the shoulders and
back
• children: normal life span and can lead long,
active lives without the use of a wheelchair
Myotonic dystrophy • also known as Steinert's
disease
• most common adult form
of MD, although half of all
cases are diagnosed in
people under 20 years old
• caused by a portion of a
particular gene that is larger
than it should be
• can appear at any time during a child's life
• muscle weakness, myotonia (in which the
muscles have trouble relaxing once they
contract), and muscle wasting, where the
muscles shrink over time
• kids: can also experience cataracts and heart
problems
Limb-girdle muscular • affects boys and girls • usually begins when kids are between 8 and 45 | P a g e
MUSCULAR DYSTROPHY
dystrophy equally 15 years old
• progresses slowly, affecting the pelvic,
shoulder, and back muscles
• severity of muscle weakness varies — some
kids have only mild weakness while others
develop severe disabilities and as adults need to
use a wheelchair
Facioscapulohumeral muscular
dystrophy
• can affect both boys and
girls
• first appears during the teen years
• tends to progress slowly
• muscle weakness first develops in the face,
making it difficult for a child to close the eyes,
whistle, or puff out the cheeks
• the shoulder and back muscles gradually
become weak, and kids have difficulty lifting
objects or raising their hands overhead
• over time, the legs and pelvic muscles also
may lose strength
46 | P a g e
MUSCULAR DYSTROPHY
Figure no-1.6 shows the clinical features of the muscular dystrophy patient
47 | P a g e
MUSCULAR DYSTROPHY
First Symptoms
Many kids with muscular dystrophy follow a normal pattern of development
during their first few years of life. But in time common symptoms begin to appear.
A child who has MD may start to stumble, waddle, have difficulty going up stairs,
and toe walk (walk on the toes without the heels hitting the floor). A child may
start to struggle to get up from a sitting position or have a hard time pushing things,
like a wagon or a tricycle.
Kids with MD often develop enlarged calf muscles (called calf pseudo
hypertrophy) as muscle tissue is destroyed and replaced by fat.
Gowers' sign is a medical sign that indicates weakness of the proximal
muscles, namely those of the lower limb. The sign describes a patient that
has to use his or her hands and arms to "walk" up his or her own body from
a squatting position due to lack of hip and thigh muscle strength.
48 | P a g e
MUSCULAR DYSTROPHY
Figure no-1.6 shows the Gowers' sign
49 | P a g e
MUSCULAR DYSTROPHY
INVESTIGATIONS
50 | P a g e
MUSCULAR DYSTROPHY
INVESTIGATIONS
DNA test
The muscle-specific isoform of the dystrophin gene is composed of
79 exons, and DNA testing and analysis can usually identify the specific type of
mutation of the exon or exons that are affected. DNA testing confirms the
diagnosis in most cases.
Muscle biopsy
If DNA testing fails to find the mutation, a muscle biopsy test may be
performed. A small sample of muscle tissue is extracted (usually with a scalpel
instead of a needle) and a dye is applied that reveals the presence of dystrophin.
Complete absence of the protein indicates the condition.
Over the past several years DNA tests have been developed that detect more
of the many mutations that cause the condition, and muscle biopsy is not required
as often to confirm the presence of Duchenne's.
Serum creatine phosphokinase measurements:
Serum creatine phosphokinase levels are more than 10 times in the elevated
muscular dystrophy patients.
Prenatal tests
If one or both parents are 'carriers' of a particular condition, there is a risk
that their unborn child will be affected by that condition. 'Prenatal tests' are carried
out during pregnancy, to try to find out if the fetus (unborn child) is affected. The
tests are only available for some neuromuscular disorders. Different types of
51 | P a g e
MUSCULAR DYSTROPHY
prenatal tests can be carried out after about 11 weeks of pregnancy. Chorion villus
sampling (CVS) can be done at 11–14 weeks, and amniocentesis after 15 weeks,
while fetal blood sampling can be done at about 18 weeks. Women and/or couples
need to consider carefully which test to have and to discuss this with their genetic
counselor. Earlier testing would allow early termination, but it carries a slightly
higher risk of miscarriage than later testing (about 2%, as opposed to 0.5%).
52 | P a g e
MUSCULAR DYSTROPHY
MEDICAL
MANAGEMENT
53 | P a g e
MUSCULAR DYSTROPHY
MEDICAL MANAGEMENT
There is no known cure for muscular dystrophy. Inactivity (such as bed
rest and even sitting for long periods) can worsen the disease. Physical therapy,
occupational therapy, orthotic intervention, speech therapy and orthopedic
instruments (e.g., wheelchairs, standing frames) may be helpful.
There is no specific treatment for any of the forms of muscular dystrophy. Physical
therapy to prevent contractures and maintain muscle tone, orthoses (orthopedic
appliances used for support) and corrective orthopedic surgery may be needed to
improve the quality of life in some cases. The cardiac problems that occur with
Emery-Dreifuss muscular dystrophy and myotonic muscular dystrophy may
require a pacemaker. The myotonia (delayed relaxation of a muscle after a strong
contraction) occurring in myotonic muscular dystrophy may be treated with
medications such as quinine, phenytoin, or mexiletine, but no actual long term
treatment has been found.
Occupational therapy assists the individual with MD in engaging in his/her
activities of daily living (self-feeding, self-care activities, etc) and leisure activities
at the most independent level possible. This may be achieved with use of adaptive
equipment or the use of energy conservation techniques. Occupational therapy may
implement changes to a person's environment, both at home or work.
54 | P a g e
MUSCULAR DYSTROPHY
SURGICAL
TREATMENT
55 | P a g e
MUSCULAR DYSTROPHY
Surgery
When contractures become more pronounced, tenotomy surgery may be
performed. In this operation, the tendon of the contractured muscle is cut, and the
limb is braced in its normal resting position while the tendon regrows. In FSH,
surgical fixation of the scapula can help compensate for shoulder weakness. For a
person with OPMD, surgical lifting of the eyelids may help compensate for
weakened muscular control. For a person with DM, sleep apnea may be treated
surgically to maintain an open airway. Scoliosis surgery is often needed in DMD
but much less often in other muscular dystrophies. Surgery is recommended at a
much lower degree of curvature for DMD than for scoliosis due to other
conditions, since the decline in respiratory function in DMD makes surgery at a
later time dangerous. In this surgery, the vertebrae are fused together to maintain
the spine in the upright position. Steel rods are inserted at the time of operation to
keep the spine rigid while the bones grow together.
When one muscle pulls much more strongly than its opposing muscle, it
may cause the joint to become partially dislocated, which is called
subluxation. Tenotomy is also performed to prevent or correct subluxation,
especially of the hip joint in cerebral palsy.
Chronic pain or bone deformity may prevent a person from moving a joint
through its full range of motion, leading to contracture.
Contracture also occurs in a variety of neuromuscular diseases, including
muscular dystrophies and polio. Degeneration of one muscle can allow the
opposing muscle to pull too hard across the joint, shortening the muscle.
56 | P a g e
MUSCULAR DYSTROPHY
Figure no-1.8 shows the Tenotomy
57 | P a g e
MUSCULAR DYSTROPHY
PHYSIOTHERAPY
ASSESMENT
PHYSIOTHERAPY ASSESSMENT
SUBJECTIVE:
Name:
58 | P a g e
MUSCULAR DYSTROPHY
Age:
Sex:
Occupation:
Address:
Present medical history:
Chief complaint-
Family history:
Duration:
Onset: gradual/sudden.
Affected site: affected parts are noted.
Past medical history:
About history of vaccinations,
History of post infections,
History of SMT.
History of medical treatment.
History of any MMR diseases during birth/childhood.
History of drugs.
History of any viral, bacterial infections.
Health condition of the members.
Position of patient in the family.
Any history of associated diseases.
59 | P a g e
MUSCULAR DYSTROPHY
Personal history:
Habits
Routine activities
Social history:
Socio- economic status
Place of living
OBJECTIVE:
On observation:
Built of the patient.
Position of the eyes.
Movements of the chestwall during expiration and
inspiration.
Any open injuries.
Any involuntarymovement of distal parts of the limbs.
Any external appliances brace, splints.etc.
Check for facial expressions.
Any deformity.
gait
Posture.
Normal activities.
On examination:
Higher function examination.
60 | P a g e
MUSCULAR DYSTROPHY
Level of consciousness.
Orientation.
Speech.
Memory.
Identification
Behavior.
Intelligence.
Examination of cranial nerves: (3,4,7 etc.,)
3rd and 4th cranial nerves: (occulomotor and trochlear)
Study the patient’s head and ask to follow an object held arm length-full
range of horizontal and vertical movements are noted.
When light is shown in to the normal eye, only the pupil on that side
consists.
7th cranial nerve: (facial nerve)
Abnormal eye movements are noted
Asymmetrical elevation of one corner of mouth is noted.
Sensory system examination:
Superficial:
61 | P a g e
MUSCULAR DYSTROPHY
Touch- soft or crude.
Pain- Superficial or deep.
Temperature- Hot OR Cold.
Deep:
Joint position.
Vibrations.
MOTOR EVALUATION:
Muscle grading.
0 – No activity is noted.
1 – Flicker of contraction.(trace)
2– Movement in elimination of gravity-One full range of motion
in gravity eliminated position.(poor)
3- movement against gravity-one full range of motion against
gravity.(fair)
4- Movements with minimal resistance. one full range of motion
against gravity with minimal resistance.(good)
5- Normal- one full range of motion
against gravity with maximal resistance.(normal)
Muscle tone –
Hypotonisity or hypertonicity.
Mostly hypotonicity is noted due to peripheral nerve involvement.
Muscle girth:
62 | P a g e
MUSCULAR DYSTROPHY
Measured by using inch tape
Reflexes:
Upper limb (decreased) Lower limb(decreased)
Absent (-) Biceps Quadriceps
Depressed (+) Triceps Tibialis anterior
Normal (+ +) Brachioradialis Plantar response.
Brisk -
Brisk with clonus-
c.) Examination of co-ordination.
Co-ordination tests for upper and lower limbs- voluntary activities of
limbs are noted.
d.) Examination of status of skin:
Pale or scaly.
Examination of ROM:
63 | P a g e
MUSCULAR DYSTROPHY
The active and passive range of motion of joints, which are affected,
should be assessed.
- Hip.
- Knee.
- Ankle
- pelvic.
- Shoulder
- Elbow
- Wrist
- Finger movements are noted.
Examination of gait:
High stepping gait.
Difficulties of gait.
Parameters of gait are noted.
64 | P a g e
MUSCULAR DYSTROPHY
Examination of posture:
Check the posture of body in various positions standing, sitting, and lying.
Check for scoliosis.
Check for kyphosis.
Check for lardosis.
Examination of respiration:
Breathing pattern.
Examine diaphragmatic components
chest wall expansion
Lung function test.
Functional assessment:
Daily activities are noted
Dependent activities are noted.
65 | P a g e
MUSCULAR DYSTROPHY
REHABILITATION
REHABILITATION
Rehabilitation is the utilization of existing capacities of the handicapped person by
the combined and co-ordinate use of medical, social, occupational, educational and
vocational measures to the optimum level of his functional abilities
66 | P a g e
MUSCULAR DYSTROPHY
Muscular Dystrophy Association
These are words of belief, relied on by our Muscular Dystrophy Association India.
Planted in early 2000, we have blossomed comfort for a large cohort of Muscular
Dystrophy community. And of course we have diagnosis and researches done to
ease the hold of the disease. With able support from more like minds, things would
prove ever positive.
Neither so early, nor late as well, the Muscular Dystrophy Association India is
one of the very few of its kind in India. Since its first breath on the 5th of February
2000, the association has itself programmed with the duty to help those afflicted by
the disease – MUSCULAR DYSTROPHY.
When the idea of such an association was kindled by Dr. Gunter
Schuebraundt on his visit to India, it was Dr. V. Viswanathan, Paediatric
Neurologist from KKCTH1, Chennai, Dr. Kalpana Gowrishankar, Geneticist,
KKCTH, Mr. Ganapathi and Ms. Kavitha, KKCTH, Mr. V. R. Anil Kumar, Rotary
Club (Madras South) and few other personalities with similar frequencies to
venture into the thought and realizing what was just an Association all but just in
mind.
With the case statistics increasing every now and then, the growing
importance on our organization have led us to where we are now. The support
group consists of the Patients, Parents, Doctors, Scientists, Volunteers and all of
those interested in alleviating the status quo of the situation and who can positively
contribute to the affected.
67 | P a g e
MUSCULAR DYSTROPHY
After six long years of experience, involvements and a shift of the
Association from its initial base at KKTCH to SMF2, Chennai, in the midway, we
have managed to establish a large cohort of Patients, Parents, and Volunteers and
like minds from all over South India. All of the patients who have registered with
us have been examined in detail and investigated on biochemical and genetic
aspect and diagnostic label established
Efforts haven’t stopped with helping the parents and children.The biggest
advantage would be meeting the challenges and sharing across culture and borders.
We are actively linked with International bodies working to find a cure for the
disease. We are one of the chosen centres for the Global programme on Duchenne
Muscular Dystrophy called the CINRG3.
Basic objectives include,
Psychological support to Patients and Parents
Dissemination of information on the disease
Promote interaction and communication amongst Doctors, Patients, Parents
and Scientists
Promote Research and Development for these ‘orphan’ disease
Create a National task Force for Public awareness
68 | P a g e
MUSCULAR DYSTROPHY
69 | P a g e
MUSCULAR DYSTROPHY
70 | P a g e
MUSCULAR DYSTROPHY
MEDICAL
Members are :
Physiatrist
Orthopedic surgeon
Neurosurgeon
Plastic surgeon
Psychiatrist
Pediatrician
Obstretrician
Geneticist
Neonatologist
Rheumatologist
Cardiologist
Cardiac surgeon
General surgeon
Oncologist
Urologist
Ophthalmologist
General physician & Family physician71 | P a g e
MUSCULAR DYSTROPHY
PARAMEDICAL
Physiotherapist
Occupational therapist
Creative movement therapist
Recreational therapist
Prosthatist –orthotist
Rehabilitation nurse
Speech pathologist
Psychologist
Biomedical engineer
Music therapist
SOCIO VOCATIONAL
Social worker
Vocational counselor
Vocational evaluator
Skilled instructor
Placement officers
Child development specialist
Special educator 72 | P a g e
MUSCULAR DYSTROPHY
Employement agencies
Some of the most important staff for the muscular dystrophy is 1.Physiotherapist
2. Occupational therapist 3.Rehabilitation nurse 4.Prosthatist –orthotist
Physiotherapist:-
Role:
a. To decrease the low back pain
b. Maintain the muscle power
c. Maintain ROM
d. Prevent deformities and contractures
e. Nutritional advise to prevent the development of obesity
f. Prevent the respiratory muscle complications
g. Maintain functional status
h. Psychological confidence
Occupational therapist:
The therapist should help return him to his occupational life and adapt him to daily
living
73 | P a g e
MUSCULAR DYSTROPHY
Rehabilitation nurse
Those nurses help him to arrange his needs and encourage and motivate the patient
in positive way
Prosthatist –orthotist:-
Those doctors will arranges the needed braces and splint to prevent him to
contracture and deformities.
74 | P a g e
MUSCULAR DYSTROPHY
PHYSIOTHERAPY
MANAGEMENT
75 | P a g e
MUSCULAR DYSTROPHY
PHYSIOTHERAPY MANAGEMENT
PROBLEM LIST:-
Low back pain
Decreased muscle power
Decreased range of motion
Development of contractures and deformities
Develop muscle wasting
Reduced respiratory muscle strength
Development of chest infections
Decreased functional status
AIMS:-
1. To decrease the low back pain
2. Maintain the muscle power
3. Maintain ROM
4. Prevent deformities and contractures
5. Nutritional advise to prevent the development of obesity
6. Prevent the respiratory muscle complications
7. Maintain functional status
Muscular dystrophy patients are in 3 stages76 | P a g e
MUSCULAR DYSTROPHY
1. Ambulatory stage.
2. Wheel chair stage.
3. Bed ridden stage.
Ambulatory stage
INTERVENTION:-
TO DECREASE LOWBACK PAIN:-
SWD applied to back to decrease pain
Spinal extension exercises should be encouraged to increase strength of
muscle
Encourage symmentrical sitting for postural correction
TO MAINTAIN MUSCLE POWER
By using MMT,strengthening of weakened muscles
Most commonly proximal muscles are involved so strengthen the proximal
muscles
TO MAINTAIN ROM
77 | P a g e
MUSCULAR DYSTROPHY
Active movement and active assisted movements should be encouraged to
maintain joint
PNF technique may be useful to increase ROM
TO PREVENT DEFORMITIES AND CONTRACTURES
The two joint muscles are most prone to developing significant contractures
Early in the course of disease process, a home program must be instituted to
include ROM, stretching and positioning
Both parents and child should get the education about the expected changes
in muscle balance
How they can pay an active role in preventing or limiting the impact of
contractures
Initially encourage the active range of motion exercises
If active ROM becomes more difficult, parents should assist the child to
move his limbs, to stretch the muscle and particular structures
The stretching program should include static stretching techniques with
prolonged mild tenson to affect both visco elastic and plastic properties of
muscle.
Positions should encouraged to prevent contractures
78 | P a g e
MUSCULAR DYSTROPHY
Once the child has significant hip flexor or IT band contracture, position the
child in a standing frame during several hours helps to provide prolonged
stretch to hip knee ankle musculature.
Encourage night splinting to control plantar flexion contracture.
Encourage long leg splint at night to prevent knee flexion contracture.
By using thoraco lumbo sacral arthosis to prevent kypotic abnormality.
effective bracing minimizes abnormal postures
PREVENT RESPIRATORY COMPLICATIONS AND IMROVE
RESPIRATORY FUNCTIONS
The child should improve breathing efficiency by the family by teaching
breathing exercises
Stressing diaphragmatic breathing
Full chest expansion exercises
Air shift and rib cage stretching
Encourage the child by playing with hand hold incentive Spiro meter units,
blowing bobbles and pin wheels.
If there are any secretions accumulated in lungs the family should be taught
postural drainage.
IMPROVE FUNCTIONAL STATUS AND MAKE THE INDIVIDUAL
FUNCTIONAL INDEPENDENCE 79 | P a g e
MUSCULAR DYSTROPHY
Encourage forced swimming
Active and resistive exercise program
Low frequency electric stimulation improves the functional status of
individual
HOME ADAPTATIONS
Rise the height of the bed, chair, toilet so that movement from one place to
another place easier.
A boat with firm mattress under it make movement and handling easier
Recreational activities include swimming riding TV Games photography
ball activities, cycling etc., should be encouraged
Bilateral KAFO use to relax.
WHEEL CHAIR STAGE AND BED BOUND STAGE:
Functional Training:-
Improving mobility function with specific emphasis on improving mobility
of axial structures, the head, trunk, hips, and shoulders. Progression to more
diffucult motor activates should be gradual. The more severely involved
patient may benefit initially from assisted movements progressing to active
movements (e.g.; the PNF technique e if R1) to improve initial motor
performance.
Moving in bed (i.e,. rolling, supine to sit transitions) are essential skills that
are often very difficult owing to rigidity and bradykinesia. Sidelyng rolling
80 | P a g e
MUSCULAR DYSTROPHY
activities that emphasize segmental rotation patterns (i.e,. isolated upper and
lower trunk rotations) shouyld be practiced rather than a log-rolling pattern.
Patients with very stiff trunks may benefit from compensatory rolling
strategies using the UE or LE to reach over and initialed the movement (eg
DIF patterns of the UE or LE to reach over and initiate the movement (eg
DIF patterns of the UE or LE).
Sitting posture can be facilitated through exercises designed to improve
pelvic mobility as the patient with PD typically sits with a stiff and posterior
titled pelvis.
Anterior and posterior tilts, side to side tilts, pelvic clock exercises can be
practiced while sitting on a therapy ball. These activities can then be
progressed to sitting on a stationary surfacce such as a mart table using an
inflatable disc to finally no apparatus,
Respiratory Training:-
Respiratory dysfunction is linked to morbidity and mortality in patients with
81 | P a g e
MUSCULAR DYSTROPHY
MD.
For these patients a comprehensive pulmonary rehabilitation programme
should be instituted.
Components include diaphragmatic breathing exercises, Air shifting
techniques, and exercises that recruited neck, shoulder, and trunk muscles.
The patient should be instructed in deep breathing exercises to improve chest
wall mobility and vital capacity.
Air shifts are promoted to lesser winterer areas of the lung for example basal
expansion can be promoted rising manual stretch and resistance to those
segments.
Upper body resistance training exercises are indicated.
Chest wall mobility can be improved by using PNF UE bilateral
symmetrical D2 flexion and extension patterns.
Motor learning stratagies:-
Walking patterns can be improved with focused instructions of "swing your
arms" walk fast or take large steps for the patient with advanced disease and
cognitive deficits, repetitive drill like practice should be used.
Visual cues inclued stationary floor markings.
Dynamic transportable cues.
UE movements were improved by reaching toward a moving target., eg a
rolling ball descending down a track.
Rhythmic auditory stimulation includes use of a metronome beat or a study
82 | P a g e
MUSCULAR DYSTROPHY
beat from musical device.
Pulsed cues to the ear lobe or the hand a form of tacktile cueing.
Group and home exercises:-
Group exercises classes can be valuable for patients with MD.
The patient can begin in the seated position and progressive standing, using
light, touchdown support of the back of the chair.
Stretching exercises involving large joints used as initial warm up activites.
Well structured low impact aerobics are an appropriate focus for a group
class, for eg patient can march in place first in sitting then in standing.
Walking with an emphasis on taking large steps high steps.
The HEP includes interventions already discussed with exercises designed to
improve relaxation mobility, flexibility, strength, and cardiopulmory
function.
Standing corner wall stretches can also be used to maintained stretch on
upper trunk flexors.
Use of cane can be effective in promoting over head motions.
Psychosocial issues
The progressive nature of PD necessitates frequent personal and social
adjustments and affects all aspects of life for both patient and family.
The principle goal for team members is to assest the patient and family in
their understanding of the disease and in developing insides and adjustments
that leads to more effective self management.
Feelings of hopelesness and dependency are reduced as patient develops a
sense of control over his life.
Patient, family and care giver education:-83 | P a g e
MUSCULAR DYSTROPHY
The therapist over all approach needs to be positive and supportive.
Community support groups are available for patients and their families.
Educate the parents abou the condition and tell the complications regarding
the problems which are faced furthers and encourage and motivate to do
home exercises which are needed.
Care giver shold encourage the patient to prevent further detoriation.
84 | P a g e
MUSCULAR DYSTROPHY
PROGNOSIS
PROGNOSIS
The prognosis for people with muscular dystrophy varies according to the
type and progression of the disorder. Some cases may be mild and progress very
85 | P a g e
MUSCULAR DYSTROPHY
slowly over a normal lifespan, while others produce severe muscle weakness,
functional disability, and loss of the ability to walk. Some children with muscular
dystrophy die in infancy while others live into adulthood with only moderate
disability. The muscles affected vary, but can be around the pelvis, shoulder, face
or elsewhere. Muscular dystrophy can affect adults, but the more severe forms tend
to occur in early childhood.
86 | P a g e
MUSCULAR DYSTROPHY
SUMMARY
SUMMARY
Muscular dystrophies (MD) are inherited disorders characterized by progressive
weakness and degeneration of the skeletal or voluntary muscles which control
movement, without a central or peripheral nerve abnormality. The muscles of the
heart and other involuntary muscles are also affected in some forms of MD, and a
few forms involve other organs as well.
10 Types of muscular dystrophy are seen in the world depending upon the part that
is involved.
1. Duchenne muscular dystrophy 87 | P a g e
MUSCULAR DYSTROPHY
2. Becker's muscular dystrophy
3. Congenital muscular dystrophy
4. Distal muscular dystrophy
5. Emery-Dreifuss muscular dystrophy
6. Facioscapulohumeral muscular dystrophy
7. Limb-girdle muscular dystrophy
8. Myotonic muscular dystrophy
9. Oculopharyngeal muscular dystrophy
10. Spinal muscular atrophy
Among the above types Duchenne muscular dystrophy is the most dangerous. The
Beckers is the second most dangerous but the life span of the Duchenne muscular
dystrophy is 12-20 but in the Beckers type above 20 years. In the Duchenne
muscular dystrophy the patient may die with respiratory complications.
No medications are available for muscular dystrophy but research are made to
control the disease progression.
88 | P a g e
MUSCULAR DYSTROPHY
BIBLIOGRAPHY
References
1. 1991 Harrison's Principles of Internal Medicine III rd edition.
2. "The muscular dystrophies" III rd edition 1995.
89 | P a g e
MUSCULAR DYSTROPHY
3. 1991 Harrison's Principles of Internal Medicine IV rd edition December
2004
4. Rehabilitation text “Muscular Dystrophy Association”.
5. http://ptct.client.shareholder.com/releasedetail.cfm?ReleaseID=448803
6. http://www.parentprojectmd.org/site/
7. R.M. Lehman & G.L. McCormack, 2001. Neurogenic and Myopathic
Dysfunction pp. 802-803.
8. Guillaume-Benjamin-Armand Duchenne 1987 Neurogenic and Myopathic
Dysfunction pp.789.
9. http://en.wikipedia.org/wiki/Muscular_dystrophy.
10.“Muscular Dystrophy Campaign” Retrieved 9 April 2007.
11."The muscular dystrophies". Lancet 359 (9307): 687–695.
12.National Institute of Neurological Disoders and Stroke .
13."Specific sequence variations within the 4q35 region are associated with
facioscapulohumeral muscular dystrophy".
14.“Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy
Therapy MYO-029.”
15.“Muscular Dystrophy Association's” website in Greece 2000.
90 | P a g e